{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T17:09:20Z","timestamp":1747847360722},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fondo de Investigaciones Sanitarias","award":["FISS-17- PI16\/01999","FISS-17- PI16\/01999"],"award-info":[{"award-number":["FISS-17- PI16\/01999","FISS-17- PI16\/01999"]}]},{"name":"VIIV Healthcare sSpain"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Long term liver fibrosis (LF) changes and their best -monitoring non-invasive markers (NILFM) after effective anti-HCV DAA therapy are little- known. Matrix-metalloproteases (MMPs) and their tissue-inhibitors (TIMPs) are pivotal in liver inflammation repair. Their plasma levels might assess long-term LF changes after therapy. Overall 374 HCV-infected adult patients, 214 HCV-HIV coinfected, were followed-up for 24\u00a0months after starting DAA. LF was assessed by transient elastometry (TE), biochemical indexes (APRI, Forns, FIB-4) and, in 61 individuals, by MMPs and TIMP-1 plasma levels. Several MMPs and TIMP-1 SNPs were genotyped in 319 patients. TE was better than biochemical indexes for early and long-term LF monitoring. MMPs-2,-8,-9 and-TIMP-1 levels and TE displayed parallel declining curves although only TIMP-1 correlated with TE (<jats:italic>P<\/jats:italic>\u2009=\u20090.006) and biochemical indexes (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.02). HCV monoinfected had significantly higher baseline NILFM and TIMP-1 plasma values, but lower MMPs levels than coinfected patients. No differences in NILFM course were observed between mono-and coinfected or between different DAA regimens. Only the <jats:italic>MMP-2 (-1306 C\/T)<\/jats:italic> variant <jats:italic>TT<\/jats:italic> genotype associated with higher values of NILFM NILFM decline extends 24\u00a0months after therapy. TE and TIMP1 are reliable LF-monitoring tools. NILFM courses were similar in mono-and coinfected patients, DAA regimens type did not influence NILFM course.<\/jats:p>","DOI":"10.1038\/s41598-022-07548-y","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T11:03:12Z","timestamp":1646823792000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV\/HIV coinfection after direct-acting antiviral therapy"],"prefix":"10.1038","volume":"12","author":[{"given":"Laura","family":"P\u00e9rez-Is","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Collazos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"de la Fuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Morano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Rivas-Carmenado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo","family":"Romero-Favela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galilea de Jes\u00fas","family":"Fonseca\u2013Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Mel\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eulalia","family":"Valle-Garay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Asensi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"7548_CR1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","volume":"10","author":"B Hajarizadeh","year":"2013","unstructured":"Hajarizadeh, B., Grebely, J. & Dore, G. Epidemiology and natural history of HCV infection. Nat. Rev. Gastroenterol. Hepato. 10, 553\u2013562. https:\/\/doi.org\/10.1038\/nrgastro.2013.107 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepato."},{"issue":"Supl9","key":"7548_CR2","doi-asserted-by":"publisher","first-page":"S745","DOI":"10.1093\/infdis\/jiaa534","volume":"222","author":"O Faldale-Nwulia","year":"2020","unstructured":"Faldale-Nwulia, O., Sulkowski, M. & Hepatitis, C. Virus treatment: simplifying the simple and optimizing the difficult. J. Infect Dis. 222(Supl9), S745-757. https:\/\/doi.org\/10.1093\/infdis\/jiaa534 (2020).","journal-title":"J. Infect Dis."},{"key":"7548_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/liv.13256","volume":"37","author":"JA Bachofner","year":"2017","unstructured":"Bachofner, J. A. et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int. 37, 369\u2013376. https:\/\/doi.org\/10.1111\/liv.13256 (2017).","journal-title":"Liver Int."},{"key":"7548_CR4","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1097\/MEG.0000000000000964","volume":"29","author":"E Dolmazashvili","year":"2017","unstructured":"Dolmazashvili, E. et al. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience. Eur. J. Gastroenterol. Hepatol. 29, 1223\u20131230. https:\/\/doi.org\/10.1097\/MEG.0000000000000964 (2017).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"7548_CR5","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/jvh.12578","volume":"23","author":"V Knop","year":"2016","unstructured":"Knop, V. et al. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J. Viral Hepat. 23, 994\u20131002. https:\/\/doi.org\/10.1111\/jvh.12578 (2016).","journal-title":"J. Viral Hepat."},{"key":"7548_CR6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s10620-017-4749-x","volume":"63","author":"J Chan","year":"2018","unstructured":"Chan, J. et al. Direct-acting antiviral therapy for chronic HCV infection results in liver stiffness regression over 12 months post-treatment. Dig. Dis. Sci. 63, 486\u2013492. https:\/\/doi.org\/10.1007\/s10620-017-4749-x (2018).","journal-title":"Dig. Dis. Sci."},{"key":"7548_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12876-019-0973-5","volume":"19","author":"WF Hsu","year":"2019","unstructured":"Hsu, W. F. et al. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents. BMC Gastroenterol. 19, 63. https:\/\/doi.org\/10.1186\/s12876-019-0973-5 (2019).","journal-title":"BMC Gastroenterol."},{"key":"7548_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000000517","author":"YC Hsieh","year":"2021","unstructured":"Hsieh, Y. C. et al. Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response. J. Chin. Med. Assoc. https:\/\/doi.org\/10.1097\/JCMA.0000000000000517 (2021).","journal-title":"J. Chin. Med. Assoc."},{"key":"7548_CR9","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.22742","volume":"49","author":"DC Rockey","year":"2009","unstructured":"Rockey, D. C. et al. Liver biopsy. Hepatology 49, 1017\u20131044. https:\/\/doi.org\/10.1002\/hep.22742 (2009).","journal-title":"Hepatology"},{"key":"7548_CR10","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jhep.2004.08.008","volume":"41","author":"K Patel","year":"2004","unstructured":"Patel, K. et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J. Hepatol. 41, 935\u2013942. https:\/\/doi.org\/10.1016\/j.jhep.2004.08.008 (2004).","journal-title":"J. Hepatol."},{"key":"7548_CR11","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1053\/j.gastro.2004.08.052","volume":"127","author":"WM Rosenberg","year":"2004","unstructured":"Rosenberg, W. M. et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127, 1704\u20131713. https:\/\/doi.org\/10.1053\/j.gastro.2004.08.052 (2004).","journal-title":"Gastroenterology"},{"key":"7548_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/hep.21984","volume":"47","author":"IN Guha","year":"2008","unstructured":"Guha, I. N. et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47, 455\u2013460. https:\/\/doi.org\/10.1002\/hep.21984 (2008).","journal-title":"Hepatology"},{"key":"7548_CR13","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1136\/gut.2010.207423","volume":"59","author":"RJ Fontana","year":"2010","unstructured":"Fontana, R. J. et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 59, 1401\u20131409. https:\/\/doi.org\/10.1136\/gut.2010.207423 (2010).","journal-title":"Gut"},{"key":"7548_CR14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/qai.0b013e3181520502","volume":"46","author":"M Larrousse","year":"2007","unstructured":"Larrousse, M. et al. Noninvasive diagnosis of hepatic fibrosis in HIV\/HCV-coinfected patients. J. Acquir. Immune Defic. Syndr. 46, 304\u2013311. https:\/\/doi.org\/10.1097\/qai.0b013e3181520502 (2007).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"7548_CR15","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001]","volume":"29","author":"L Sandrin","year":"2003","unstructured":"Sandrin, L. et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med. Biol. 29, 1705\u20131713. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2003.07.001] (2003).","journal-title":"Ultrasound Med. Biol."},{"key":"7548_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018]","volume":"128","author":"L Cast\u00e9ra","year":"2005","unstructured":"Cast\u00e9ra, L. et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128, 343\u2013350. https:\/\/doi.org\/10.1053\/j.gastro.2004.11.018] (2005).","journal-title":"Gastroenterology"},{"key":"7548_CR17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","volume":"48","author":"L Castera","year":"2008","unstructured":"Castera, L., Forns, X. & Alberti, A. Non-invasive evaluation of liver fibrosis using transient elastography. J. Hepatol. 48, 835\u2013847. https:\/\/doi.org\/10.1016\/j.jhep.2008.02.008 (2008).","journal-title":"J. Hepatol."},{"key":"7548_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3851\/IMP1708","volume":"16","author":"JA Carton","year":"2011","unstructured":"Carton, J. A. et al. Factors associated with liver fibrosis in intravenous drug users coinfected with HIV and HCV. Antiviral Ther. 16, 27\u201335. https:\/\/doi.org\/10.3851\/IMP1708 (2011).","journal-title":"Antiviral Ther."},{"key":"7548_CR19","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/cid\/ciaa702","volume":"73","author":"N Kronfli","year":"2021","unstructured":"Kronfli, N. et al. Liver fibrosis in human immunodeficiency virus (HIV)-hepatitis C virus (HCV) coinfection before and after sustained virologic response: what is the best noninvasive marker for monitoring regression?. Clin. Infect Dis. 73, 468\u2013747. https:\/\/doi.org\/10.1093\/cid\/ciaa702 (2021).","journal-title":"Clin. Infect Dis."},{"key":"7548_CR20","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/cid\/ciaa698","volume":"73","author":"JK Rockstroh","year":"2021","unstructured":"Rockstroh, J. K. Noninvasive markers for monitoring fibrosis regression after hepatitis C virus cure What do they promise. Clin. Infect Dis. 73, 478\u2013479. https:\/\/doi.org\/10.1093\/cid\/ciaa698 (2021).","journal-title":"Clin. Infect Dis."},{"key":"7548_CR21","doi-asserted-by":"publisher","unstructured":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update. J Hepatol 75, 659\u2013689 (2021). https:\/\/doi.org\/10.1016\/j.jhep.2021.05.025","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"7548_CR22","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/nri1418","volume":"4","author":"WC Parks","year":"2004","unstructured":"Parks, W. C., Wilson, C. L. & L\u00f3pez-Boado, Y. Matrix metaloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4, 617\u2013629. https:\/\/doi.org\/10.1038\/nri1418 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"7548_CR23","doi-asserted-by":"publisher","first-page":"9184","DOI":"10.3390\/ijms15069184","volume":"15","author":"CM Mastroiani","year":"2014","unstructured":"Mastroiani, C. M., Lichtner, M., Mascia, C., Zuccala, P. & Vullo, V. Molecular mechanisms of liver fibrosis in HIV\/HCV coinfection. Int. J. Mol Sci. 15, 9184\u20139208. https:\/\/doi.org\/10.3390\/ijms15069184 (2014).","journal-title":"Int. J. Mol Sci."},{"key":"7548_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jceh.2017.09.004","volume":"7","author":"A Naim","year":"2017","unstructured":"Naim, A., Pan, Q. & Baig, M. S. Matrix metalloproteinases (MMPs) in liver diseases. J. Clin. Exp. Hepatol. 7, 367\u2013372. https:\/\/doi.org\/10.1016\/j.jceh.2017.09.004 (2017).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"7548_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/hep.510310114","volume":"31","author":"TH Kim","year":"2000","unstructured":"Kim, T. H., Mars, W. M., Stolz, D. B. & Michalopoulos, G. K. Expression and activation of pro-MMP2 and pro-MMP9 during rat liver regeneration. Hepatology 31, 75\u201382. https:\/\/doi.org\/10.1002\/hep.510310114 (2000).","journal-title":"Hepatology"},{"key":"7548_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1468-1293.2010.00836.x","volume":"12","author":"J Macias","year":"2011","unstructured":"Macias, J. et al. Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV\/hepatitis C virus-coinfected patients. HIV Med. 12, 14\u201321. https:\/\/doi.org\/10.1111\/j.1468-1293.2010.00836.x (2011).","journal-title":"HIV Med."},{"key":"7548_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/s0009-8981(01)00730-6","volume":"316","author":"KHW Boeker","year":"2002","unstructured":"Boeker, K. H. W. et al. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin. Chem. Acta 316, 71\u201381. https:\/\/doi.org\/10.1016\/s0009-8981(01)00730-6 (2002).","journal-title":"Clin. Chem. Acta"},{"key":"7548_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1572-0241.2004.04055.x","volume":"99","author":"V Leroy","year":"2004","unstructured":"Leroy, V. et al. Circulating matrix metalloproteonsases 1, 2, 9, and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: Comparison with PIIINP and hyaluronic acid. Am. J. Gastroenterol. 99, 271\u2013279. https:\/\/doi.org\/10.1111\/j.1572-0241.2004.04055.x (2004).","journal-title":"Am. J. Gastroenterol."},{"key":"7548_CR29","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/liv.12139","volume":"33","author":"SS El-Kamary","year":"2013","unstructured":"El-Kamary, S. S. et al. Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection. Liver Int. 33, 982\u2013990. https:\/\/doi.org\/10.1111\/liv.12139 (2013).","journal-title":"Liver Int."},{"key":"7548_CR30","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.dld.2020.05.004","volume":"52","author":"T Medeiros","year":"2020","unstructured":"Medeiros, T. et al. Liver fibrosis improvement in chronic hepatitis C after direct acting-antivirals is accompanied by reduced profibrogenic biomarkers-a role for MMP-9\/TIMP-1. Dig. Liver Dis. 52, 1170\u20131177. https:\/\/doi.org\/10.1016\/j.dld.2020.05.004 (2020).","journal-title":"Dig. Liver Dis."},{"key":"7548_CR31","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.cardiores.2005.07.015","volume":"69","author":"S Ye","year":"2006","unstructured":"Ye, S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc. Res. 69, 636\u2013645. https:\/\/doi.org\/10.1016\/j.cardiores.2005.07.015 (2006).","journal-title":"Cardiovasc. Res."},{"key":"7548_CR32","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1038\/srep05002","volume":"4","author":"G Martin","year":"2014","unstructured":"Martin, G. et al. Role of plasma matrix-metalloproteases (MMPs) and their polymorphisms (SNPs) in sepsis development and outcome in ICU patients. Sci. Rep. 4, 5002. https:\/\/doi.org\/10.1038\/srep05002 (2014).","journal-title":"Sci. Rep."},{"key":"7548_CR33","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2310\/JIM.0b013e3182a32e24","volume":"61","author":"MG S\u00e1nchez-Parada","year":"2013","unstructured":"S\u00e1nchez-Parada, M. G. et al. Association of genetic polymorphisms with histological grading of necroinflammation, staging of fibrosis, and liver function in Mexicans with chronic hepatitis C virus infection. J. Investig. Med. 61, 1088\u20131096. https:\/\/doi.org\/10.2310\/JIM.0b013e3182a32e24 (2013).","journal-title":"J. Investig. Med."},{"key":"7548_CR34","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1245\/s10434-011-1574-x","volume":"18","author":"TY Chen","year":"2011","unstructured":"Chen, T. Y. et al. Role of MMP14 gene polymorphisms in susceptibility and pathological development to hepatocellular carcinoma. Ann. Surg. Oncol. 18, 2348\u20132356. https:\/\/doi.org\/10.1245\/s10434-011-1574-x (2011).","journal-title":"Ann. Surg. Oncol."},{"key":"7548_CR35","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.kjms.2018.06.006","volume":"34","author":"JW Liu","year":"2018","unstructured":"Liu, J. W. & Chen, D. Q. Correlations of MMP-2 and MMP-9 gene polymorphisms with the risk of hepatopulmonary syndrome in cirrhotic patients: a case-control study. Kaohsiung J. Med. Sci. 34, 634\u2013642. https:\/\/doi.org\/10.1016\/j.kjms.2018.06.006 (2018).","journal-title":"Kaohsiung J. Med. Sci."},{"key":"7548_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/clinchem\/46.2.183","volume":"46","author":"R Lichtinghagen","year":"2000","unstructured":"Lichtinghagen, R. et al. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin. Chem. 46, 183\u2013192 (2000).","journal-title":"Clin. Chem."},{"key":"7548_CR37","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/QAD.0b013e328018751d","volume":"21","author":"T Latronico","year":"2007","unstructured":"Latronico, T. et al. Antiretroviral therapy inhibits matrix metalloproteinase-9 from blood mononuclear cells of HIV-infected patients. AIDS 21, 677\u2013684. https:\/\/doi.org\/10.1097\/QAD.0b013e328018751d (2007).","journal-title":"AIDS"},{"key":"7548_CR38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5501\/wjv.v6.i2.36","volume":"6","author":"J Collazos","year":"2017","unstructured":"Collazos, J. et al. Matrix metalloproteases and their tissue inhibitors in non-alcoholic liver fibrosis of human immunodeficiency virus-infected patients. World J. Virol. 6, 34\u201365. https:\/\/doi.org\/10.5501\/wjv.v6.i2.36 (2017).","journal-title":"World J. Virol."},{"key":"7548_CR39","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1053\/jhep.2001.23002","volume":"33","author":"NA Callejas","year":"2001","unstructured":"Callejas, N. A., Casado, M., Diaz-Guerra, M. J., Bosc\u00e1, L. & Martin-Sanz, P. Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology 33, 860\u2013867. https:\/\/doi.org\/10.1053\/jhep.2001.23002 (2001).","journal-title":"Hepatology"},{"key":"7548_CR40","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1136\/gut.2003.038364","volume":"53","author":"O N\u00fa\u00f1ez","year":"2004","unstructured":"N\u00fa\u00f1ez, O. et al. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 53, 1665\u20131672. https:\/\/doi.org\/10.1136\/gut.2003.038364 (2004).","journal-title":"Gut"},{"key":"7548_CR41","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/ijms17040455","volume":"17","author":"T Latronico","year":"2016","unstructured":"Latronico, T. et al. Liver fibrosis in HCV monoinfected and HIV\/HCV coinfected patients dysregulation of matrix metalloproteinases (MMPs) and their tissue inhibitors TIMPs and effect of HCV protease inhibitors. Int. J. Mol. Sci. 17, 455. https:\/\/doi.org\/10.3390\/ijms17040455 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"7548_CR42","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai, C. T. et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38, 518\u2013526. https:\/\/doi.org\/10.1053\/jhep.2003.50346 (2003).","journal-title":"Hepatology"},{"key":"7548_CR43","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/jhep.2002.36128]","volume":"36","author":"X Forns","year":"2002","unstructured":"Forns, X. et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36, 986\u2013992. https:\/\/doi.org\/10.1053\/jhep.2002.36128] (2002).","journal-title":"Hepatology"},{"key":"7548_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.21669","volume":"46","author":"A Vallet-Pichard","year":"2007","unstructured":"Vallet-Pichard, A. et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 46, 32\u201336. https:\/\/doi.org\/10.1002\/hep.21669 (2007).","journal-title":"Hepatology"},{"key":"7548_CR45","doi-asserted-by":"publisher","first-page":"11644","DOI":"10.1158\/0008-5472.CAN-06-1212","volume":"66","author":"AK Kader","year":"2006","unstructured":"Kader, A. K. et al. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res. 66, 11644\u201311648. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1212 (2006).","journal-title":"Cancer Res."},{"key":"7548_CR46","first-page":"4165","volume":"8","author":"P Wu","year":"2015","unstructured":"Wu, P., Hua, Y., Li, M., Shu, Y. & Fang, G. Interactions of central obesity with rs3918242 on risk of non-alcoholic fat liver disease. A preliminary case-control study. Int. J. Clin. Exp. Pathol. 8, 4165\u20134170 (2015).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"7548_CR47","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.kjms.2018.06.006","volume":"34","author":"JW Liu","year":"2018","unstructured":"Liu, J. W. & Chen, D. Q. Correlations of MMP-2 and Mp-9 gene polymorphisms with the risk of hepatopulmonary syndrome in cirrhotic patients: a case-control study. Kaohsiung J. Med. Sci. 34, 634\u2013642. https:\/\/doi.org\/10.1016\/j.kjms.2018.06.006 (2018).","journal-title":"Kaohsiung J. Med. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07548-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07548-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07548-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T23:36:19Z","timestamp":1669332979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07548-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7548"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-07548-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"assertion":[{"value":"23 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3828"}}